# SELLAS Life Sciences (SLS) — Earnings

SLS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/sls/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.07 |
| EPS estimate | −$0.08 |
| EPS surprise | +8.74% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1390478/000139047825000016/sls-20250630.htm) |

SELLAS Life Sciences reported Q2 2025 results on August 12, 2025. It posted a loss of $0.07 per share, slightly narrower than the $0.08 loss expected, a beat of 8.74%. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2024, the loss was $0.13 per share, so the loss narrowed by about 46%.

Every quarter in the table is a loss, but they have shrunk. Full-year totals went from $2.13 per share in 2022 to $1.34 in 2023 and $0.50 in 2024, and the first half of 2025 added up to $0.14. The widest quarterly loss in the table was $1.05 in Q1 2022, and the narrowest was $0.06 in Q4 2024. Revenue appears in only three early quarters, the largest being $5.7 million in Q1 2021. The table skips Q4 2021. Of the 19 quarters with an estimate, SELLAS beat 9 times and missed 10 times, but it beat in each of the last five.

The table holds no results after Q2 2025. Past third-quarter reports came out between November 9 and November 14. The next report in the table will show whether the quarterly loss stays near $0.07 per share.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$0.08 | −$0.07 | 8.74% | — | — |
| Q1 2025 | May 13, 2025 | −$0.11 | −$0.07 | 33.33% | — | — |
| Q4 2024 | Mar 20, 2025 | −$0.11 | −$0.06 | 43.77% | — | — |
| Q3 2024 | Nov 13, 2024 | −$0.13 | −$0.10 | 21.07% | — | — |
| Q2 2024 | Aug 13, 2024 | −$0.17 | −$0.13 | 24.99% | — | — |
| Q1 2024 | May 14, 2024 | −$0.16 | −$0.21 | -31.25% | — | — |
| Q4 2023 | Mar 28, 2024 | $0.09 | −$0.23 | -365.28% | $13.0M | — |
| Q3 2023 | Nov 9, 2023 | $0.02 | −$0.33 | -1985.71% | $13.0M | — |
| Q2 2023 | Aug 10, 2023 | −$0.36 | −$0.31 | 12.68% | — | — |
| Q1 2023 | May 11, 2023 | −$0.29 | −$0.47 | -62.07% | — | — |
| Q4 2022 | Mar 16, 2023 | −$0.32 | −$0.33 | -3.13% | — | — |
| Q3 2022 | Nov 14, 2022 | −$0.39 | −$0.34 | 12.08% | — | — |
| Q2 2022 | Aug 11, 2022 | −$0.36 | −$0.41 | -12.85% | — | — |
| Q1 2022 | May 12, 2022 | −$0.38 | −$1.05 | -176.32% | — | $1.0M |
| Q3 2021 | Nov 12, 2021 | −$0.36 | −$0.45 | -25.00% | — | — |
| Q2 2021 | Aug 12, 2021 | −$0.41 | −$0.30 | 25.93% | — | $1.9M |
| Q1 2021 | May 13, 2021 | −$0.18 | −$0.16 | 11.11% | — | $5.7M |
| Q4 2020 | Mar 23, 2021 | −$0.19 | −$0.43 | -126.32% | — | — |
| Q3 2020 | Nov 13, 2020 | −$0.27 | −$0.53 | -96.30% | — | — |
| Q2 2020 | Aug 13, 2020 | $0.00 | −$0.66 | 0.00% | — | — |

## Frequently Asked Questions

### When did SELLAS Life Sciences (SLS) last report earnings?

SELLAS Life Sciences last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did SLS beat earnings estimates?

Yes. SELLAS Life Sciences reported EPS of −$0.07 for Q2 2025 against a −$0.08 estimate — a 8.74% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).